m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00715)
Name
Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone
Status
Investigative
Structure
Formula
C14H11Br2N3OS
InChI
1S/C14H11Br2N3OS/c15-10-3-1-2-8(6-10)13(18-19-14(17)21)9-4-5-12(20)11(16)7-9/h1-7,20H,(H3,17,19,21)/b18-13-
InChIKey
UIMSYLGHIQKPJZ-AQTBWJFISA-N
PubChem CID
136002679
TTD Drug ID
D04DFX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cathepsin B (CTSB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cathepsin B (CTSB) is a therapeutic target for Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone through regulating the expression of Cathepsin B (CTSB). [1], [2]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005 Dec 1;48(24):7535-43. doi: 10.1021/jm0504961.